Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

After a year of significant disruption at Novo Nordisk, the company's R&D chief has told Fierce Biotech that the deal-hungry ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Novo Nordisk anticipates oral weight-loss drugs will capture one-third or more of the GLP-1 market by 2030, driven by ...

Speaking at the J.P. Morgan Healthcare Conference, Doustdar said compounders recognized consumer behavior earlier than major ...

TUESDAY, Jan. 6, 2026 (HealthDay News) — A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo ...